Prevalencia del síndrome metabólico en hipertensos estadio I

Abstract

Introduction and motivationIt is important for recently diagnosed systemic hypertension (HPB) individuals to verify the existence of other cardiovascular risk factors, in order to establish optimal treatment strategies. Knowing the prevalence of metabolic syndrome (MS) in patients with stage 1 HBP. MethodsProspective, observational, cross-sectional study conducted over one year in Bogotá, Medellin, Cali and Barranquilla in individuals of both genders, ≥ 18 and ≤ 60 years old with recently diagnosed stage 1 HBP and without drug therapy. Presence of MS was verified for all subjects according to recent consensus of the International Diabetes Federation, the National Heart, Lung and Blood Institute, the American Heart Association, the World Heart Federation, the International Atherosclerosis Society and the International Association for the Study of Obesity. ResultsAverage prevalence of MS in the total population of hypertensive patients was of 16.84%. In Cali it was of 28.8%, in Medellin of 18.9%, in Barranquilla of 12.5% and in Bogotá of 11.4%. Medellin showed the highest prevalence in men (14.7%) and Cali in women (15.2%). ConclusionsIt is recommended to conduct a systematic search for MS in patients who have recently been diagnosed with HBP. Prevalence among MS in the studies Colombian cities varied greatly. More studies are required to find out about the real prevalence of MS in patients with HBP in other Colombian cities and to implement educational studies to minimise its impact.